Medworxx Patient Flow Solution Continues to Expand in the UK with Adoption from Basildon and Thurrock University Hospitals NHS Foundation Trust

TORONTO--()--Medworxx Solutions Inc. ("Medworxx") (TSX VENTURE:MWX) today announced Basildon and Thurrock University Hospitals NHS Foundation Trust (BTUH) has licensed the Medworxx Clinical Criteria Module to be installed in a multi-phase Clinical Utilisation Review (CUR) deployment across the Acute Trust and ultimately into neighbouring Community based services, covering close to 700 beds across several locations. BTUH has been successfully appointed by NHS England as an early Implementer of the National CUR CQUIN Scheme and provides an extensive range of acute services for 405,000 people living in south-west Essex. The Essex Cardiothoracic Centre is also part of the Trust, providing a full range of tertiary cardiothoracic services for the whole county and further afield. Phase one of the locally hosted implementation includes a strategic rollout across the Cardiothoracic Centre’s three wards, with Phase two including all general medicine beds.

BTUH’s decision to license Medworxx came as a result of a CUR snapshot audit, delivered in February 2015. The results identified opportunities for whole system patient flow improvement which were shared with the local System Resilience Group, and provided decision makers with the necessary evidence to select the Medworxx Clinical Criteria Module - designed to provide advanced patient flow analytics in real-time to support improvements in MDT discharge and system integration. In 2014 NHS England introduced a substantial Commissioning for Quality and Innovation scheme (CQUIN) to support providers in adopting CUR technology for specialised admitted patient care and critical care in 2015/16.

The goal of the CUR CQUIN is to improve patient flow, enhance quality and ensure patients are treated in the most appropriate clinical settings, freeing up staff time and hospital resources. BTUH represents one of five Trusts selected by NHS England to be early CQUIN adopters. Medworxx currently supports three of the five adopters, who have all selected to utilise the Medworxx patient flow software for CUR. “We are eager to utilise our CQUIN funding. Our partnership with Medworxx showed us how resources, as reported in the diagnostic review, can be sustained and built upon by embedding the Medworxx tool as part of our current clinical utilisation program,” said Nigel Kee, Chief Operating Officer, Basildon and Thurrock University Hospitals NHS Foundation Trust.

“This is an exciting time for Medworxx and for CUR development in the UK. We welcome BTUH to our client community, as we work together to standardise admit and discharge decision making for appropriateness of inpatients,” said Dan Matlow, President and Chief Executive Officer, Medworxx. “For the first time, BTUH will be able to conduct rapid assessments and collect transparent information and data on individual patient progress and discharge planning in real-time.”

About Medworxx
Medworxx delivers health information technology solutions to over 400 hospitals internationally; including Canada, France, United States and United Kingdom. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Utilisation Management—flagship of Medworxx Patient Flow that includes electronic bed board and independent assessment components—currently serves 32%of the acute care beds in Canada.
Visit: http://www.medworxx.com/

Disclaimer
The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company’s expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.

Contacts

Medworxx UK
Peter Ellis, +44-(0)20-7730-9614
Managing Director
pellis@medworxx.com
or
Medworxx
Dan Matlow, 416-642-1278 x311
1-800-321-1591
President & Chief Executive Officer
dmatlow@medworxx.com
or
Investor Relations
APEX Capital Inc.
Katrin Tosine, 647-388-4984
Director of Capital Markets
ktosine@apexcap.ca

Release Summary

Medworxx Patient Flow Solution continues to expand in the UK with adoption from Basildon and Thurrock University Hospitals NHS Foundation Trust

Contacts

Medworxx UK
Peter Ellis, +44-(0)20-7730-9614
Managing Director
pellis@medworxx.com
or
Medworxx
Dan Matlow, 416-642-1278 x311
1-800-321-1591
President & Chief Executive Officer
dmatlow@medworxx.com
or
Investor Relations
APEX Capital Inc.
Katrin Tosine, 647-388-4984
Director of Capital Markets
ktosine@apexcap.ca